[go: up one dir, main page]

WO2018100017A1 - Procédé et système permettant le traitement d'échantillons biologiques - Google Patents

Procédé et système permettant le traitement d'échantillons biologiques Download PDF

Info

Publication number
WO2018100017A1
WO2018100017A1 PCT/EP2017/080894 EP2017080894W WO2018100017A1 WO 2018100017 A1 WO2018100017 A1 WO 2018100017A1 EP 2017080894 W EP2017080894 W EP 2017080894W WO 2018100017 A1 WO2018100017 A1 WO 2018100017A1
Authority
WO
WIPO (PCT)
Prior art keywords
fixed cell
electromagnetic radiation
cell sample
sample
retrieval agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2017/080894
Other languages
English (en)
Inventor
Heidi BARNETT
Andrew M. HANNON
James E. PHILLIPS-PORTILLO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Ventana Medical Systems Inc
Original Assignee
F Hoffmann La Roche AG
Ventana Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Ventana Medical Systems Inc filed Critical F Hoffmann La Roche AG
Publication of WO2018100017A1 publication Critical patent/WO2018100017A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/44—Sample treatment involving radiation, e.g. heat
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis

Definitions

  • the present disclosure relates to a method and system for unmasking protein antigens and nucleic acid targets from fixed biological samples, and more particularly, to a method and system for unmasking antigens and targets in fixed biological samples using ultraviolet light.
  • Fixation of tissue and cell samples is used to help ensure that the morphology of the sample and the spatial distribution of biomolecules is preserved and thus used for the basis of a diagnosis by a pathologist.
  • the presence of particular proteins and/or nucleic acid sequences can be used to further characterize a disease state and, in some instances, is used by an oncologist to direct therapy of the disease.
  • fixation can also interfere with the detection of proteins and nucleic acids in a sample.
  • an unmasking step also known as “antigen retrieval” or “target retrieval” for IHC and ISH, respectively
  • protein antigens or nucleic acid targets accessible to detection reagents such as antibodies or probes.
  • NBF neutral- buffered formalin
  • the present disclosure provides methods and systems that facilitate the detection of protein and/or nucleic acid targets in a sample.
  • the present disclosure is a method for preparing a fixed cell sample for analysis, the method including contacting the sample with a retrieval agent and exposing the fixed cell sample to electromagnetic radiation, the electromagnetic radiation having a wavelength of between about 10 nm and about 400 nm (UV radiation). In some embodiments, the electromagnetic radiation has a wavelength of between about 200 nm and about 400 nm. In some embodiments, the electromagnetic radiation has a wavelength of between about 250 nm and about 400nm.
  • the electromagnetic radiation includes one or more of UVA radiation (having a wavelength ranging from about 315nm to about 400 nm), UVB radiation (having a wavelength ranging from about 280nm to about 315 nm), and UVC radiation (having a wavelength ranging from about lOOnm to about280 nm).
  • the retrieval agent is an antigen retrieval agent which includes one or more of water, a buffer, an enzyme, a chaotropic reagent, a chelating agent, a nucleophile, an oxidizing agent, an organic acid/base pair, an electron-deficient compound such as a Lewis acid, and a surfactant.
  • the antigen retrieval agent includes at least two of water, a buffer, an enzyme, a chaotropic reagent, a chelating agent, a nucleophile, an oxidizing agent, an organic acid/base pair, an electron-deficient compound such as a Lewis acid, and a surfactant.
  • the antigen retrieval agent includes at least three of water, a buffer, an enzyme, a chaotropic reagent, a chelating agent, a nucleophile, an oxidizing agent, an organic acid/base pair, an electron-deficient compound such as a Lewis acid, and a surfactant.
  • the antigen retrieval agent includes a buffer (e.g. TRIS) and has a pH ranging from about 7 to about 9.
  • the method includes exposing the sample to one or more of heat, microwaves and ultrasound.
  • the sample is heated to between about 60 C and about 150 C.
  • when the sample is heating it can be held under pressure to minimize evaporation of the antigen retrieval agent or mitigate or prevent the boiling of the antigen retrieval agent.
  • an automated system for treating a fixed cell sample mounted on a substrate including a substrate holder configured to hold the substrate, and a reagent dispenser configured to dispense a retrieval agent, e.g. an antigen retrieval agent, onto the fixed cell sample.
  • the system includes an electromagnetic radiation source configured to direct UV electromagnetic radiation toward the fixed cell sample.
  • UV electromagnetic radiation directed toward the fixed cell sample has wavelength of between about 200 nm and about 400 nm.
  • the system also includes a controller configured to control the dispenser and the electromagnetic radiation source to deliver the retrieval agent and direct the electromagnetic radiation (at a suitable wavelength or range of wavelengths) to the fixed cell sample mounted on the substrate.
  • the controller directs the operation of the dispenser and/or radiation source to operate according to a predetermined sequence and/or for a predetermined amount of time. In some embodiments, the controller optionally enables the direction of electromagnetic radiation toward the sample at a predetermined intensity or at a predetermined radiation flux.
  • the substrate holder includes a heating element. In some embodiments, the substrate holder is enclosed in a pressurizable chamber.
  • the system includes a source of microwave radiation that can be used to heat the sample and/or the retrieval agent. In some embodiments, the microwave radiation employed has a wavelength ranging from between about 7.5 cm to about 15 cm. In some embodiments, the substrate is glass. In some embodiments, the substrate is a microscope slide.
  • an apparatus for the treatment of a fixed cell sample including a pressurizable chamber, a removable rack for mounting one or more substrates holding one or more fixed cell samples, and a UV light source configured to operate within the pressurizable chamber and direct UV light onto the one or more fixed cell samples.
  • a central UV light source is surrounded by a sample rack that fits around the periphery of the pressurizable chamber.
  • FIG. 1 is a set of images showing the UV reactor apparatus used to expose the tissue samples shown in FIGS. 1 and 2 to UV light, where panel A is the outside of the UV reactor apparatus, panel B is a view from the top of the reactor showing the UV light sources arranged around the periphery, and panel C shows the tray in which slides were held at the bottom of the reactor apparatus.
  • FIG. 2 is set of micrographs illustrating the effect of ultraviolet treatment according to a disclosed method on FFPET tonsil tissue samples stained for the protein BCL-2, where panel A shows a positive control sample obtained by conventional heat-induced antigen retrieval using a citrate buffer solution; panel B shows the results for 2 hours of UV light exposure combined with contacting the sample with citrate buffer; panel C shows the results for 1 hour of UV light exposure; panel D shows the results for 30 minutes of UV light exposure; and panel E shows a control sample that was covered with foil and placed alongside the UV light exposed slides for the maximum exposure of 2 hours.
  • panel A shows a positive control sample obtained by conventional heat-induced antigen retrieval using a citrate buffer solution
  • panel B shows the results for 2 hours of UV light exposure combined with contacting the sample with citrate buffer
  • panel C shows the results for 1 hour of UV light exposure
  • panel D shows the results for 30 minutes of UV light exposure
  • panel E shows a control sample that was covered with foil and placed alongside the UV light exposed slides for the maximum exposure of 2 hours.
  • FIG. 3 is a set of micrographs at a higher magnification that correspond to the micrographs of FIG. 2, where panel A shows a positive control sample obtained by conventional heat-induced antigen retrieval using a citrate buffer solution; panel B shows the results for 2 hours of UV light exposure combined with contacting the sample with citrate buffer; panel C shows the results for 1 hour of UV light exposure; panel D shows the results for 30 minutes of UV light exposure; and panel E shows a control sample that was covered with foil and placed alongside the UV light exposed slides for the maximum exposure of 2 hours.
  • FIG. 4 is a schematic of an embodiment of the disclosed automated system for treating biological samples on microscope slides.
  • FIG. 5 is a top-view schematic showing an embodiment of the disclosed apparatus for treatment of a fixed cell sample according to a disclosed method.
  • the phrase "at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
  • This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase "at least one" refers, whether related or unrelated to those elements specifically identified.
  • At least one of A and B can refer, in one embodiment, to at least one, optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.
  • a method involving steps a, b, and c means that the method includes at least steps a, b, and c.
  • steps and processes may be outlined herein in a particular order, the skilled artisan will recognize that the ordering steps and processes may vary unless a particular order is clearly indicated by the context.
  • the term “about” refers to a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated.
  • the term “about” generally refers to a range of numerical values (e.g., +/— 5-10% of the recited value) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In some instances, the term “about” may include numerical values that are rounded to the nearest significant figure.
  • the term “substantially” means the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. In some embodiments, “substantially” means within about 20%. In some embodiments, “substantially” means within about 15%. In some embodiments, “substantially” means within about 10%. In some embodiments,
  • antigen refers to a compound, composition, or substance that may be specifically bound by the products of specific humoral or cellular immunity, such as an antibody molecule or T-cell receptor.
  • Antigens can be any type of molecule including, for example, haptens, simple intermediary metabolites, sugars (e.g., oligosaccharides), lipids, and hormones as well as macromolecules such as complex carbohydrates (e.g., polysaccharides), phospholipids, nucleic acids and proteins.
  • biological sample refers to any sample including a biomolecule (such as a protein, a peptide, a nucleic acid, a lipid, a carbohydrate, or a combination thereof) that is obtained from any organism including viruses.
  • a biomolecule such as a protein, a peptide, a nucleic acid, a lipid, a carbohydrate, or a combination thereof
  • Other examples of organisms include mammals (such as humans; veterinary animals like cats, dogs, horses, cattle, and swine; and laboratory animals like mice, rats and primates), insects, annelids, arachnids, marsupials, reptiles, amphibians, bacteria, and fungi.
  • Biological samples include tissue samples (such as tissue sections and needle biopsies of tissue), cell samples (such as cytological smears such as Pap smears or blood smears or samples of cells obtained by microdissection), or cell fractions, fragments or organelles (such as obtained by lysing cells and separating their components by centrifugation or otherwise).
  • tissue samples such as tissue sections and needle biopsies of tissue
  • cell samples such as cytological smears such as Pap smears or blood smears or samples of cells obtained by microdissection
  • cell fractions, fragments or organelles such as obtained by lysing cells and separating their components by centrifugation or otherwise.
  • biological samples include blood, serum, urine, semen, fecal matter, cerebrospinal fluid, interstitial fluid, mucous, tears, sweat, pus, biopsied tissue (for example, obtained by a surgical biopsy or a needle biopsy), nipple aspirates, cerumen, milk, vaginal fluid, saliva, swabs (such as buccal swabs), or any material containing biomolecules that is derived from a first biological sample.
  • the term "biological sample” as used herein refers to a sample (such as a homogenized or liquefied sample) prepared from a tumor or a portion thereof obtained from a subject.
  • the term "cell sample” refers to a biological sample comprising cells or a morphological portion thereof, which cells can be individual cells or can be arranged together in a tissue structure.
  • the cell sample is a collection of cells (such as blood or cervical cells) placed onto a microscope slide.
  • the cell sample is a frozen tissue section placed on a microscope slide.
  • the cell sample is a formalin-fixed paraffin-embedded tissue sample (FFPET sample), prepared by first fixing a collection of cells or a piece of tissue using formalin, which is then processed using know techniques to dehydrate the sample, clear the sample and impregnate the sample in a block of paraffin (or other materials) such that it can be sliced into thin sections that are placed onto a microscope slide for treatment and analysis.
  • FLPET sample formalin-fixed paraffin-embedded tissue sample
  • the term "fixed cell sample” refers to a biological sample that has been treated to help preserve the morphological and/or biochemical features of the cells as they existed before the biological sample was obtained from the organism or alternatively before the sample was obtained from a culture of material originally obtained from a biological sample (e.g.
  • a fixed cell sample can, for example, be prepared by contacting the sample with an aldehyde fixative such as formaldehyde or glutaraldehyde.
  • a fixed cell sample can be prepared by contacting the sample with an alcohol-based fixative such as one including methanol, ethanol or acetic acid.
  • a fixed cell sample can be prepared by contacting the sample with an oxidizing agent such as osmium tetraoxide or potassium permanganate, or a fixed cell sample can be prepared using a metallic based fixative such as mercuric chloride or picric acid.
  • a fixed cell sample is prepared by contacting a biological sample comprising cells with a neutral buffered formalin (NBF) solution, which is typically used as a solution that is about 3.7% formalin (10% formaldehyde and 1% methanol).
  • NVF neutral buffered formalin
  • the term "slide” refers to any substrate (e.g., substrates made, in whole or in part, glass, quartz, plastic, silicon, etc.) of any suitable dimensions on which a biological specimen is placed for analysis, and more particularly to a "microscope slide” such as a standard 3 inch (7.62 cm) by 1 inch (2.54 cm) microscope slide or a standard 75 mm by 25 mm microscope slide.
  • target refers to any molecule for which the presence, location and/or concentration is or can be determined.
  • target molecules include proteins, epitopes, nucleic acid sequences, and haptens, such as haptens covalently bonded to proteins.
  • Target molecules are typically detected using one or more conjugates of a specific binding molecule and a detectable label.
  • the terms “unmask” or “unmasking” refer to retrieving antigens and/or improving the detection of amino acids, peptides, and proteins in a fixed tissue.
  • the method includes contacting the sample with a retrieval agent and exposing the sample to UV radiation.
  • the UV radiation is electromagnetic radiation having a wavelength of between about 10 nm and about 400 nm.
  • the UV radiation is electromagnetic radiation having a wavelength of between about 200 nm and about 400 nm.
  • the UV radiation is electromagnetic radiation having a wavelength of between about 250 nm and about 400 nm.
  • the UV radiation is applied to the fixed cell sample for a predetermined amount of time.
  • the predetermined amount of time is a time period that is sufficient to unmask at least one antigen that was masked during the fixation process.
  • the predetermined time can be established empirically by comparing a staining pattern for the at least one antigen (or target) before and after the exposure to the UV radiation.
  • the staining pattern may be determined using a computer system, such as one coupled to an imaging device, the computer system comprising one or more processors and a memory, such as a non-transitory memory.
  • UV radiation is introduced for a time period of about 2 hours or less. In some embodiments, UV radiation is introduced for a time period ranging from between about 1 minute to about 1 hour. In some embodiments, UV radiation is introduced for a time period ranging from between about 1 minute to about 45 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 1 minute to about 30 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 2 minutes to about 30 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 3 minutes to about 30 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 2 minutes to about 15 minutes.
  • UV radiation is introduced for a time period ranging from between about 5 minutes to about 20 minutes. In other embodiments, UV radiation is introduced for a time period ranging from between about 5 minutes to about 15 minutes. In some embodiments, the time for UV irradiation depends on the frequency of the UV radiation, the angle of incidence from the UV radiation source to the sample, and/or the proximity of the UV radiation source to the sample.
  • the UV radiation is introduced in pulses, i.e. where the UV radiation source is "on” for a period of time, followed by a period of time where the UV radiation source is "off.”
  • the UV radiation source may be turned “on” for a period of time ranging from between about 0.5 seconds and about 60 seconds, followed by a period of time in which the UV radiation source is turned “off for a period of time ranging from between about 0.5 seconds to about 60 seconds.
  • the retrieval agent comprises water and/or an aqueous buffer solution.
  • the sample is also heated, such as to a temperature ranging from between about 30 C to about 150 C.
  • the sample is heated for a predetermined amount of time (e.g. 10 seconds, 30 seconds, 60 seconds, etc.).
  • the predetermined time of heating can coincide with a predetermined time of exposure to UV radiation, or could be shorter or longer time period, and can itself be established empirically by comparing a staining pattern for at least one antigen (or target) before and after the combination of UV treatment and heat exposure of the sample.
  • Procedures for heating, such as by microwave heating, are described by Shan-Rong
  • the fixed cell sample can be exposed to UV radiation and also be exposed to microwave radiation.
  • the microwave radiation includes electromagnetic radiation having a wavelength ranging from between about 0.1 cm to about 100 cm. In some embodiments, the microwave radiation includes electromagnetic radiation having a wavelength of between about 0.75 cm and about 100 cm. In some embodiments, the microwave radiation includes electromagnetic radiation having a wavelength of between about 7.5 cm and about 15 cm. In some embodiments, the microwave radiation is applied to the sample for a predetermined amount of time.
  • the exposure time for the microwave radiation can be sufficient to raise the temperature of the sample and/or the retrieval agent in contact with sample, or it could be applied in bursts so as to not significantly raise the temperature of the sample (e.g. pulses of microwave radiation of a predetermined number of seconds followed by pauses between pulses of a predetermined number of seconds).
  • the predetermined time and pattern of exposure to the microwave radiation can be empirically established by comparing a staining pattern for at least one antigen (or target) before and after the particular combination of UV and microwave radiation exposure.
  • a combination of UV exposure, microwave exposure (continuous or in bursts), and heating of the fixed cell sample can be applied to sufficiently unmask a particular antigen so that it can be detected in the fixed cell sample.
  • a fixed cell sample can be exposed to ultrasound energy in addition to the UV radiation and/or microwave radiation for a predetermined amount of time.
  • the time, length and intensity of any or all of the different electromagnetic energies or radiation can be established empirically by comparing a pattern of staining for a particular antigen (or target), as noted herein.
  • the retrieval agent can be a buffer solution having a pH ranging from between about 5 and about 10. In particular embodiments, the retrieval agent can be a buffer solution having a pH ranging from between about 7 and about 9. In other particular embodiments, the retrieval agent can comprise a buffer solution having a pH ranging from between about 7.5 and about 11.
  • buffers include citric acid, potassium dihydrogen phosphate, boric acid, diethyl barbituric acid, piperazine-N,N'-bis(2-ethanesulfonic acid), dimethylarsinic acid, 2-(N-morpholino)ethanesulfonic acid, tris(hydroxymethyl)methylamine (TRIS), 2-(N-morpholino)ethanesulfonic acid
  • TPS N,N-bis(2-hydroxyethyl)glycine(Bicine), N- tris(hydroxymethyl)methylglycine
  • Tricine 4-2-hydroxyethyl-l- piperazineethanesulfonic acid
  • TES ⁇ [tris(hydroxymethyl)methyl] amino ⁇ ethanesulfonic acid
  • the retrieval agent includes a tris based buffer with a slightly basic pH. In other embodiments, the retrieval agent includes about 100 mM Tris, the retrieval agent having a pH of between about 8 and about 10. In other embodiments, the retrieval agent includes about 0.05% citraconic anhydride. In other embodiments, the retrieval agent includes about 10 mM citrate with about 2 mM EDTA and with about 0.05% Tween 20, the retrieval agent having a pH of about 6.2. In other embodiments, the retrieval agent includes about 0.01M citrate buffer, the retrieval agent having a pH of about 6.0.
  • the retrieval agent can include a reagent that reacts with any liberated fixative so as to prevent it from reacting again with the sample.
  • a reagent that reacts with any liberated fixative include purpald or dimedone that are used to determine formaldehyde concentrations because they form very stable products.
  • the retrieval agent can include a reagent that reacts in a reversible manner with free amino-groups of proteins and thus protects them from reaction with any available formaldehyde.
  • a reagent that reacts in such a reversible manner is citraconic anhydride (CCA).
  • the retrieval agent can include a chelator such as ethylenediammetetraacetic acid (EDTA).
  • chelators include ethylene glycol-bis(P-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), EGTA/ AM (EGTA, Tetra(acetoxymethyl Ester)), (l,2-bis(o- aminophenoxy)ethane-N,N,N ⁇ N'-tetraacetic acid) (BAPTA), BAPTA/AM (EGTA Tetra(acetoxymethyl Ester)), 5 , 5 '-Dimethy 1-B APT A- AM ; l,2-Bis(2-amino-5- methylphenoxy) ethane (MAPTAM), N,N,N',N'-tetrakis(2-pyridylmethyl)ethane- 1,2-diamine (TPEN), citrate, or ionophores such as ethylenediammetetraace
  • the retrieval agent can include an enzyme.
  • an enzyme that can be included in the retrieval agent are a proteinase (such as trypsin, chymotrypsin, pepsin, or proteinase K), a nuclease, a glycanase, and a hyaluronidase.
  • the retrieval agent can include a chaotropic agent.
  • chaotropic agents include butanol, ethanol, a guanidinium salt (for example, guanidinium hydrochloride or guanidinium thiocyanate), lithium perchlorate, lithium acetate, magnesium chloride, phenol, propanol, thiourea and urea.
  • the retrieval agent can include a nucleophile, i.e. a chemical species that donates an electron pair to an electrophile.
  • nucleophiles include ammonia, primary amines, secondary amines and tertiary amines.
  • Other examples of nucleophiles include hydrazines, alcohols and halogenides.
  • the retrieval agent can include a Lewis acid.
  • Lewis acids include metal ions such as iron (III) ions, aluminium ions, magnesium ions or other electron-deficient compounds such as toluenesulfonic acid, boric acid, boron trifluoride, and tartaric acid.
  • the retrieval agent can include a surfactant.
  • surfactants are classified as anionic, cationic, or nonionic, depending on their mode of chemical action. In general, surfactants reduce interfacial tension between two liquids.
  • An example of a surfactant is sodium dodecyl sulfate.
  • nonionic surfactants include polyethylene glycol monohexadecyl ether, Cetostearyl alcohol, Cetyl alcohol, cocamide diethanolamine, cocamide monoethanolamine, Decyl glucoside, Octylphenoxypolyethoxyethanol, Polyethylene glycol monoisohexadecyl ether, Lauryl glucoside, Nonyl phenoxypolyethoxylethanol, 4-Nonylphenyl-polyethylene glycol, 1 -(4-Nonylphenyl)- 1, 4, 7, 10, 13, 16,19,22,25-nonaoxaheptacosan-27-ol, nonoxynols, Monolaurin, Octaethylene glycol monododecyl ether, Oleyl alcohol, Polyethylene-polypropylene glycol, Polyglycerol polyricinoleate, Polysorbates, Sorbitan monostearate.
  • Sorbitan tristearate Stearyl alcohol; polyethylene glycol p- (l,l,3,3-tetramethylbutyl)-phenyl ether; Polyoxyethylene (20) sorbitan monooleate. octyl-, decyl, dodecyl-glucopyranoside, -maltoside or deoxycholic acid.
  • Exemplary surfactants are sold under the names: Brij® 35, TWEEN®, TergitolTM, TritonTM, EcosurfTM, DowfaxTM, polysorbate 80TM, BigCHAP, Deoxy BigCHAP, IGEPAL®, Saponin, Thesit®, Nonidet®, Pluronic F-68, digitonin, deoxycholate, and the like. Particular disclosed working embodiments concern using surfactants selected from Brij® 35, TWEEN®, TergitolTM, TritonTM.
  • the retrieval agent comprises deionized water, TRIS, and a chelator.
  • the retrieval agent comprises deionized water, TRIS, and a chelator and has a pH ranging from between about 7 to about 9.5.
  • the retrieval agent comprises deionized water, TRIS, a chelator, and a preservative.
  • the retrieval agent is CC1, available from Ventana Medical Systems, Inc., Arlington, AZ, USA.
  • the retrieval agent can include one, some or all of the different types of compounds listed above, and that the retrieval agent can be used in combination with UV radiation and one or more of microwave radiation, heat and ultrasound energy.
  • the automated system includes a substrate holder configured to hold the substrate.
  • a reagent dispenser is configured to dispense a retrieval agent onto the fixed cell sample, and a UV radiation source is configured to direct electromagnetic radiation toward the fixed cell sample.
  • the automated system includes a controller that is configured to control the reagent dispenser to dispense the retrieval agent and to direct UV radiation toward the fixed cell sample in a predetermined sequence and for a predetermined amount of time.
  • the source of UV radiation can be any known or future developed source of UV radiation, including, without limitation, an LED emitting a particular range of UV wavelengths or an array of LED lamps emitting a narrow spectrum of UV light or a broad spectrum of UV light, a mercury vapor lamp, a UV LED laser, or a xenon lamp, or any combination thereof.
  • the source of UV radiation can be a source of one or more of UVA,
  • the source of UV radiation can include wavelengths of between about 200 nm and about 400 nm.
  • the automated system includes an enclosure surrounding one or more substrate holders, which enclosure can be pressurizable.
  • the substrate holder can include a heating and/or cooling element (e.g. a conductive heating element or a Peltier heating and cooling element).
  • the substrate holder can be automatically moveable under the direction of the controller into and out of the enclosure, such as through a door that can be sealed once the substrate holder is moved into the enclosure. Any of the slide holders disclosed in U.S. Patent Nos. 8,663,991;
  • a substrate mover can be used to automatically place the substrate holding the fixed cell sample onto a stationary substrate holder kept inside the enclosure, such as through a sealable door mechanism.
  • the automated system can include a source of microwave radiation and/or a source of ultrasound energy, such that microwaves or ultrasound are applied to the sample, such as at predetermined wavelengths or frequencies.
  • the microwave radiation and or the ultrasound energy is applied for a predetermined period of time.
  • microwave radiation or ultrasound energy is introduced for a time period ranging from between about 1 minute to about 60 minutes.
  • microwave radiation or ultrasound energy is introduced for a time period ranging from between about 2 minutes to about 30 minutes.
  • microwave radiation or ultrasound energy is introduced for a time period ranging from between about 3 minutes to about 15 minutes.
  • microwave radiation or ultrasound energy is introduced for a time period ranging from between about 5 minutes to about 15 minutes.
  • a larger system such as a specimen processing apparatus, might include other modules for performing other procedures on the substrate mounted biological samples, such as deparrafmization procedures, the application of antibodies and probes to the sample, drying, coverslipping, incubating and the like.
  • a specimen processing apparatus may be utilized to apply a wide range of substances to the specimen.
  • the substances include, without limitation, stains, probes, reagents, rinses, and/or conditioners (hereinafter collectively referred to as "stains").
  • the substances can be fluids (e.g., gases, liquids, or gas/liquid mixtures), or the like.
  • the fluids can be solvents (e.g., polar solvents, non-polar solvents, etc.), solutions (e.g., aqueous solutions or other types of solutions), or the like.
  • Reagents can include, without limitation, stains, wetting agents, antibodies (e.g., monoclonal antibodies, polyclonal antibodies, etc.), antigen recovering fluids (e.g., aqueous- or non-aqueous-based antigen retrieval solutions, antigen recovering buffers, etc.), or the like.
  • Probes can be an isolated nucleic acid or an isolated synthetic oligonucleotide, attached to a detectable label or reporter molecule. Labels can include radioactive isotopes, enzyme substrates, co-factors, ligands, chemiluminescent or fluorescent agents, haptens, and enzymes.
  • the specimen processing apparatus can be an automated apparatus, such as the BENCHMARK XT instrument and SYMPHONY instrument sold by Ventana Medical Systems, Inc. Ventana Medical Systems, Inc. is the assignee of a number of United States patents disclosing systems and methods for performing automated analyses, including U.S. Pat. Nos. 5,650,327, 5,654,200, 6,296,809,
  • H&E stainers include the VENTANA SYMPHONY (individual slide stainer) and VENTANA HE 600 (individual slide stainer) series H&E stainers from Roche; the Dako CoverStainer
  • the contactless mixer describes herein may be added to any of the aforementioned specimen processing systems.
  • an apparatus for the treatment of a fixed sample that includes a chamber, which in some embodiments is pressurizable.
  • the apparatus includes a removable rack configured to fit inside the chamber and to hold one or more substrates holding one or more fixed cells. Examples of suitable apparatuses include those described in United States Patent
  • a UV light source (which can be any know or future developed source of UV light, such as noted herein) that is configured to operate within the chamber and direct UV light onto the one or more fixed cell samples.
  • a UV light source (which can be any know or future developed source of UV light, such as noted herein) that is configured to operate within the chamber and direct UV light onto the one or more fixed cell samples.
  • FIG. 1 studies were performed to determine the effectiveness of UV radiation in unmasking protein antigens using a Rayonet RPR- 200 Photochemical Reactor that is shown in panel A of FIG. 1.
  • the interior of the UV reactor includes a number of UV lamps arranged around the periphery of the chamber. Microscope slides bearing tissue samples were placed into the container shown in panel C of FIG.
  • FPET Formalin-fixed paraffin-embedded tissue
  • a counter stain was applied. First one drop of hematoxylin was applied to the sample and allowed to incubate for 4 minutes under a coverslip. Next, a drop of bluing reagent was applied under a coverslip and allowed to incubate for an additional 4 min, and then coverslipped. [0057] As a pair of controls, an additional sample of tonsil tissue was subjected to a standardized, automated heat-induced antigen retrieval procedure on the followed by BCL-2 detection (BenchMark Ultra system, Ventana Medical Systems, Inc., Arlington, AZ, USA) and another sample was placed into the UV reactor for 2 hours, but covered with aluminum foil to prevent UV light from reaching the sample.
  • BCL-2 detection BenchMark Ultra system, Ventana Medical Systems, Inc., Arlington, AZ, USA
  • Control is shown which is stained according to a standardized heat-induced antigen retrieval procedure (i.e. heating of the sample or antigen retrieval agent), and where no UV light was applied to the sample.
  • a standardized heat-induced antigen retrieval procedure i.e. heating of the sample or antigen retrieval agent
  • UV light was applied to the sample.
  • the brown staining of the BCL-2 protein is clearly evident.
  • panel E of FIG. 2 is shown a micrograph of the control slide which received neither heat-induced antigen retrieval treatment according to the standardized procedures, nor any exposure to UV light. Little brown BCL-2 staining is evident in this control slide.
  • panels B, C and D of FIG. 2 are micrographs of tonsil samples exposed to UV light for 2 hours, 1 hour and 30 minutes, respectively.
  • FIG. 4 shows a schematic diagram of an embodiment of an automated system 100 according to the disclosure that may be used to automatically treat fixed cell samples with UV light according to the disclosed methods.
  • the apparatus of FIG. 4 shows a schematic diagram of an embodiment of an automated system 100 according to the disclosure that may be used to automatically treat fixed cell samples with UV light according to the disclosed methods.
  • the apparatus of FIG. 4 shows a schematic diagram of an embodiment of an automated system 100 according to the disclosure that may be used to automatically treat fixed cell samples with UV light according to the disclosed methods. The apparatus of FIG.
  • enclosure 102 which may or may not be pressurizable
  • UV source 104 that is positioned above substrate holder 108 on which microscope slide (substrate) 110 is placed and on top of which microscope slide 110 is fixed cell sample 112.
  • reagent dispenser 106 which can be used to dispense a retrieval agent onto the fixed cell sample 112, and thereafter UV source 104 can direct UV radiation onto the fixed cell sample 112 for a predetermined amount of time.
  • An example of a reagent dispenser is described in US Patent No. 8,790,596, the disclosure of which is hereby incorporated by reference herein in its entirety.
  • a controller can be used to turn the UV light source on an off, and to actuate a pump, syringe, pipette (or the like) to dispense a retrieval agent onto the fixed cell sample 112.
  • substrate holder 108 can include a heating or cooling mechanism (such as a conductive heater or a Peltier device).
  • a heating or cooling mechanism such as a conductive heater or a Peltier device.
  • An example of a slide heating device is described in US Patent Nos. 7,425,306 and 6,582,962, the disclosures of which are hereby incorporated by reference herein in their entireties.
  • hot air or steam could be introduced into enclosure 102 to raise the temperature of the fixed cell sample 112. Where enclosure 102 is able to be pressurized, it is possible to raise the temperature within the enclosure without inducing boiling of the retrieval agent in contact with fixed cell sample 112.
  • FIG. 5 shows a top view of a different embodiment of an apparatus 200 for carrying out the disclosed methods.
  • apparatus 200 includes housing 202, which can include a lid (not show) and can be pressurizable.
  • Removable rack 204 holds substrates 206a, 206b, 206c, 206d, 206e, 206f, 206g, and 206h, which although not shown explicitly, could hold fixed cell samples on either the surface facing the UV light source 208 or on the opposite surface.
  • the apparatus of FIG. 5 can be used for manual treatment of fixed cell samples according to the disclosed methods, or for semi-automated methods (such as where the device includes a timer for turning UV light source 208 on an off after a pre-determined amount of time.
  • UV light source 208 would advantageously be enclosed in a liquid-proof housing such that the interior space of the housing 202 could be filled with a retrieval agent solution. As discussed with respect to the system of FIG.
  • the housing 202 could be pressurized to prevent boiling of the retrieval agent during the treatment process, particularly if the housing 202 also includes a heating element for raising the internal temperature of the apparatus.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des procédés et des systèmes permettant de révéler des antigènes protéiques et des cibles d'acides nucléiques dans des échantillons cellulaires fixes à l'aide d'une lumière UV. Dans certains modes de réalisation, une exposition à la lumière UV est combinée avec d'autres procédés et agents de révélation, ce qui permet d'assurer que des entités moléculaires difficiles à révéler sont rendues détectables de manière fiable.
PCT/EP2017/080894 2016-12-01 2017-11-30 Procédé et système permettant le traitement d'échantillons biologiques Ceased WO2018100017A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662428977P 2016-12-01 2016-12-01
US62/428,977 2016-12-01

Publications (1)

Publication Number Publication Date
WO2018100017A1 true WO2018100017A1 (fr) 2018-06-07

Family

ID=60812018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/080894 Ceased WO2018100017A1 (fr) 2016-12-01 2017-11-30 Procédé et système permettant le traitement d'échantillons biologiques

Country Status (1)

Country Link
WO (1) WO2018100017A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110016492A (zh) * 2019-04-15 2019-07-16 吉林金域医学检验所有限公司 一种革兰氏染色法
CN110361348A (zh) * 2019-08-22 2019-10-22 赵云红 一种用于水质检测的总氮检测系统及其总氮检测方法
CN113785184A (zh) * 2019-05-14 2021-12-10 文塔纳医疗系统公司 包括生物学样品处理腔室的系统

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007031874A2 (fr) * 2005-07-01 2007-03-22 Dako Denmark A/S Procede de visualisation simultanee de multiples cibles biologiques
US20100028978A1 (en) * 2005-05-24 2010-02-04 Angros Lee H In situ heat induced antigen recovery and staining apparatus and method
US20150148243A1 (en) * 2013-11-22 2015-05-28 Samsung Electronics Co., Ltd. Method for reversible fixation or selective lysis of cell using photocleavable polymer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028978A1 (en) * 2005-05-24 2010-02-04 Angros Lee H In situ heat induced antigen recovery and staining apparatus and method
WO2007031874A2 (fr) * 2005-07-01 2007-03-22 Dako Denmark A/S Procede de visualisation simultanee de multiples cibles biologiques
US20150148243A1 (en) * 2013-11-22 2015-05-28 Samsung Electronics Co., Ltd. Method for reversible fixation or selective lysis of cell using photocleavable polymer

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110016492A (zh) * 2019-04-15 2019-07-16 吉林金域医学检验所有限公司 一种革兰氏染色法
CN113785184A (zh) * 2019-05-14 2021-12-10 文塔纳医疗系统公司 包括生物学样品处理腔室的系统
CN110361348A (zh) * 2019-08-22 2019-10-22 赵云红 一种用于水质检测的总氮检测系统及其总氮检测方法
CN110361348B (zh) * 2019-08-22 2021-12-03 海南聚兴环保科技有限公司 一种用于水质检测的总氮检测系统及其总氮检测方法

Similar Documents

Publication Publication Date Title
DK1337831T3 (en) REMOVAL OF BIOLOGICAL SAMPLING AND CELL CONDITIONING MEDIA ON AUTOMATIC DYING INSTRUMENTS
US20140273088A1 (en) Method, apparatus and system for staining of biological samples
JP2004525366A (ja) 自動免疫組織化学およびイン・サイチュ・ハイブリダイゼーションのアッセイ処方
US20240335840A1 (en) Non-contact, on-slide fluid mixing
DK2300799T3 (en) Process for the histo chemical processing and use of a composition for histo chemical processing
CA2543043A1 (fr) Traitement tissulaire simplifie
WO2009085574A2 (fr) Extraction d'antigènes par énergie micro-onde dans des solvants non aqueux
WO2018100017A1 (fr) Procédé et système permettant le traitement d'échantillons biologiques
EP2467695B1 (fr) Appareil et procédé pour une infiltration tissulaire accélérée au moyen d'une excitation micro-onde
EP2122324B1 (fr) Extraction d'antigene a l'horizontale
JP3797418B2 (ja) 抗原賦活化法及びその抗原賦活剤
US20250067637A1 (en) Phenol-free acid-fast bacteria solution
US8530808B2 (en) Microwave-assisted heating and processing techniques
Bratthauer Processing of tissue specimens
AU2014208296B2 (en) Compositions comprising nanomaterials and method for using such compositions for histochemical processes
Itaya et al. Immunohistochemistry of p53, Bcl-2, and Ki-67 as predictors of chemosensitivity
US20230407379A1 (en) Electric field aided sample preparation
Mawuli Immunohistochemistry Application in Laboratory Medicine: Current Approaches and Challenges
JP2005221511A (ja) 生物学的試料からの包埋媒体の除去および自動化された染色装置における細胞コンディショニング
human Ig-kappa et al. For the simultaneous qualitative detection of human Ig-kappa (κ) and Ig-lambda (λ) mRNA by chromogenic in situ hybridization (CISH)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17821481

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17821481

Country of ref document: EP

Kind code of ref document: A1